Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201469
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Perelló Bratescu, Aina | - |
dc.contributor.author | Dürsteler, Christian | - |
dc.contributor.author | Álvarez Carrera, Maria Asunción | - |
dc.contributor.author | Granés, Laura | - |
dc.contributor.author | Kostov, Belchin | - |
dc.contributor.author | Sisó Almirall, Antoni | - |
dc.date.accessioned | 2023-08-02T11:30:33Z | - |
dc.date.available | 2023-08-02T11:30:33Z | - |
dc.date.issued | 2022-01-20 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | http://hdl.handle.net/2445/201469 | - |
dc.description.abstract | In chronic non-cancer pain (CNCP), evidence of the effectiveness of strong opioids (SO) is very limited. Despite this, their use is increasingly common. To examine SO prescriptions, we designed a descriptive, longitudinal, retrospective population-based study, including patients aged >= 15 years prescribed SO for >= 3 months continuously in 2013-2017 for CNCP in primary care in Catalonia. Of the 22,691 patients included, 17,509 (77.2%) were women, 10,585 (46.6%) were aged >80 years, and most had incomes of <euro18,000 per year. The most common diagnoses were musculoskeletal diseases and psychiatric disorders. There was a predominance of transdermal fentanyl in the defined daily dose (DDD) per thousand inhabitants/day, with the greatest increase for tapentadol (312% increase). There was an increase of 66.89% in total DDD per thousand inhabitants/day for SO between 2013 (0.737) and 2017 (1.230). The mean daily oral morphine equivalent dose/day dispensed for all drugs was 83.09 mg. Transdermal fentanyl and immediate transmucosal release were the largest cost components. In conclusion, there was a sustained increase in the prescription of SO for CNCP, at high doses, and in mainly elderly patients, predominantly low-income women. The new SO are displacing other drugs. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics14020237 | - |
dc.relation.ispartof | Pharmaceutics, 2022, vol. 14, num. 2, p. 237 | - |
dc.relation.uri | https://doi.org/10.3390/pharmaceutics14020237 | - |
dc.rights | cc by (c) Perelló Bratescu, Aina et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | Opiacis | - |
dc.subject.classification | Avaluació del risc per la salut | - |
dc.subject.classification | Tractament del dolor | - |
dc.subject.other | Opioids | - |
dc.subject.other | Health risk assessment | - |
dc.subject.other | Pain treatment | - |
dc.title | Trends in the Prescription of Strong Opioids for Chronic Non-Cancer Pain in Primary Care in Catalonia: Opicat-Padris-Project | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-07-04T07:28:26Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9299329 | - |
dc.identifier.pmid | 35213969 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Trends in the Prescription of Strong Opioids for Chronic Non-Cancer Pain in Primary Care in Catalonia_Pharmaceutics.pdf | 781.7 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License